D-0616-2017 Class II Terminated

Recalled by Claris Lifesciences Inc — North Brunswick, NJ

FDA drug recall D-0616-2017 was initiated by Claris Lifesciences Inc on Mar 10, 2017 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product. The recall status is terminated (terminated Sep 18, 2020). Affected quantity: 72072 units.

Recall details

Product Type
Drugs
Report Date
Apr 5, 2017
Initiation Date
Mar 10, 2017
Termination Date
Sep 18, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
72072 units

Product description

Metronidazole Injection, USP, 500 mg/100 mL, Rx only, Manufactured for: Claris Lifesciences Inc. North Brunswick NJ, 08902, By: Claris Injectable Ltd. Gujarat, India, NDC 36000-001-24

Reason for recall

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Distribution pattern

Nationwide

Code information

Lot #: A060205; A060209, Exp.Jan 2018

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0616-2017
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0616-2017. Report a data issue: hello@regdatalab.com.